Heidi H. van Ojik

FcγRI (CD64) Contributes Substantially to Severity of Arthritis, Hypersensitivity Responses, and Protection from Bacterial Infection

A. Ioan-Facsinay, Sjef J. de Kimpe, Sandra M. M. Hellwig et al. · Immunity · 2002 · 297 citations · Full text

Inflammation, Rheumatology, Allergy +14

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

Wim H.J. Kruit, Heidi H. van Ojik, Vincent Brichard et al. · International Journal of Cancer · 2005 · 156 citations

Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy

Wim K. Bleeker, Jeroen J. Lammerts van Bueren, Heidi H. van Ojik et al. · The Journal of Immunology · 2004 · 149 citations · Full text

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

Heidi H. van Ojik, Lisette Bevaart, Christopher E. Dahle et al. · PubMed · 2003 · 93 citations

Lymphoid Neoplasia, Gene Therapies, Cancer Immunosurveillance +15

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

Roland Repp, Heidi H. van Ojik, Thomas Valerius et al. · British Journal of Cancer · 2003 · 87 citations · Full text